CXCR2 and neoplasm: Indeed, it was found that although targeting CCR2+ TAMs or CXCR2+ TANs alone can enhance anti-tumor immunity, unfortunately, this leads to a compensatory influx of alternative myeloid subset, which result persistent immunosuppressive TME.